MedImpact Achieves Record-Low Trend

Commercial plans realize the lowest drug spend to date — with only a 1.6 percent increase

MedImpact released its 2017 Annual Trend Report — reavealing record-low trend results in 2017 at its Annual Conference last week in San Diego. In spite of rising drug prices for established drugs and blockbuster innovator drugs, MedImpact achieved record-low drug trend across commercial, Medicare and Medicaid lines of business in 2017.

Commercial plans saw the lowest trend increase — just 1.6% compared to 2.9% in 2016. Unsurprisingly, commercial specialty trend was 10.2% in 2017, representing only 1% of claim volume, but accounting for 41% of total spend.

With the impact of recent merger and acquisition activities and high-impact, high-cost specialty and orphan drugs dominating the drug pipeline, plan sponsors contend with numerous, competing market dynamics impacting budgets across both the pharmacy and medical benefits, including:

  • A move toward vertical integration as health plans acquire PBMs or PBMs acquire health plans
  • Market entry of high-cost, innovative specialty and orphan drugs
  • Renewed debate over value, reimbursement, access and eligibility for costly but highly effective cell-based therapies, gene therapies and regenerative medicines

The 2017 Annual Trend Report details MedImpact’s success at managing trend in the face of rising drug costs, providing critical data and industry insights — and advanced trend management solutions to help drive low-net cost and lower prescription drug costs.

Download Annual Trend Report

  • Email